Betamethasone
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Betamethasone: Alopecia mucinosa
One-Sentence Summary
Betamethasone is a corticosteroid with anti-inflammatory and immunosuppressive actions, marketed in Australia as topical products. The TxGNN model predicts it may be useful for alopecia mucinosa (follicular mucinosis). Support is very limited: no registered clinical trials and 1 publication, a 1964 case series with a review of therapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for betamethasone is not available in the data compiled for this report. Betamethasone is a corticosteroid, a class that reduces inflammation and suppresses immune activity.
Alopecia mucinosa (follicular mucinosis) involves mucin deposition in the follicular epithelium, often with an inflammatory infiltrate around the hair follicle. Corticosteroids could plausibly reduce that inflammation, so the link is reasonable but indirect. The only supporting publication is a 1964 case series, and no modern trials exist. The prediction should be treated as a hypothesis, not as demonstrated efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14164963 | 1964 | Case series / Review | Archives of Dermatology | Report of three cases of follicular mucinosis (alopecia mucinosa) with a review of therapy. No abstract is available, so the findings for betamethasone cannot be confirmed. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10794D | Betnovate 1/2 | Cream 500 micrograms (as valerate) per g, 15 g | Not recorded in the local data |
| ARTG 10795E | Diprosone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Not recorded in the local data |
Both entries are single-ingredient products with a valid status. Both are topical presentations.
Safety Considerations
Drug Interactions (100 interactions were recorded; examples below):
- Major: adalimumab
- Moderate: zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, albiglutide, aldesleukin, alefacept, alemtuzumab, fluvoxamine, fosamprenavir, tetanus toxoid vaccine
- Minor: formoterol, salbutamol
Product-specific warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (0.9997), but the only direct evidence is a single 1964 case series with no abstract and no registered trials. The mechanistic link is plausible but indirect.
To proceed, the following is needed:
- Retrieval and review of the full text of the 1964 case series, to check whether topical corticosteroids such as betamethasone were used and what the outcomes were
- A systematic search for more recent case series, cohorts or trials on topical or intralesional corticosteroids in follicular mucinosis
- Mechanism of action data for betamethasone
- Product Information warnings and contraindications for the Australian products
- A review of the suitability of the available topical cream and ointment for the affected sites, such as the scalp
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.